India, Sept. 2 -- image credit- shutterstock

Ahmedabad-based Zydus Lifesciences has announced the launch of its trivalent influenza (Flu) vaccine VaxiFlu introduced for the first time in India, aligning with the global recommendations of WHO.

Flu remains a significant global health concern of seasonal influenza annually, causing 3-5 million cases of severe illness with 290,000 to 650,000 respiratory deaths annually. The disease disproportionately affects vulnerable populations such as infants, the elderly, and individuals with chronic conditions.

Vaxiflu - Trivalent Influenza Vaccine (TIV) is recommended for individuals aged 6 months and above. It contains latest, updated strains selected based on WHO's annual surveillance and recommen...